Some harsh truths about Cel-Sci's cancer drug

Multikine, an immunotherapy for head and neck cancer, is destined to fail in Phase 3 — or so says STAT’s Adam Feuerstein. And yet, in the months since his treatise on the predicted fate of the small-cap biotech, Cel-Sci’s stock has instead tripled. 

Was Adam wrong about Cel-Sci? No way. It’s a ploy, he says, in which the company continues to release misleading information about the Multikine trial. He put together a series of myths and facts regarding the study of the experimental treatment.

Read more.